PD-1 positivity was found in 37.8% of squamous cell carcinomas, 28.6% of adenosquamous carcinomas, and 16.7% of endocervical adenocarcinomas in 1 investigation of cervical malignancies.[3] Additionally, patients were enrolled in the phase 3 EMPOWER CERVICAL 1/GOG 3016/ ENGOT cx9 trial, regardless of their PD-L1 status. Here, PDCD1 is linked to adenosquamous carcinoma.